From: Posttranslational control of lipogenesis in the tumor microenvironment
Drugs | Targeted protein | Cancer type | Function | ClinicalTrial. gov identifier | Status |
---|---|---|---|---|---|
TVB-2640 | FASN | Advanced tumors | To inhibit FASN | NCT02223247 | Completed |
TVB-2640 | FASN | Breast and colon cancer | To inhibit FASN | NCT03179904 | Recruiting |
CLA | FASN | Breast cancer | To inhibit FASN | NCT00908791 | Completed |
Statins | HMGCR | Solid tumors | To inhibit HMGCR | NCT02285738 | Completed |
Metformin | AMPK | Acute lymphoblastic leukemia | To activate AMPK | NCT03118128 | Recruiting |
Metformin | AMPK | Breast, endometrial, Prostate cancer | To activate AMPK | NCT01620593 | Completed |
Lapatinib | AMPK | Metastatic breast cancer | To activate AMPK | NCT01477060 | Terminated |
RGX-104 | LXRs | Lung and endometrial cancer | To activate LXRs | NCT02922764 | Recruiting |
NRX194204 | RXR | Non-small cell lung cancer | agonist of RXR | NCT01540071 | Active |
Bexarotene | RXR | Cutaneous T-cell lymphoma | To activate RXR | NCT01007448 | recruiting |
Pioglitazone | PPARa | Bladder cancer | agonist of PPARa | NCT01637935 | Completed |
TPST-1120 | PPARa | Hepatocellular carcinoma | antagonist of PPARα | NCT03829436 | Active |